Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sanofi has launched a Phase 2a clinical study titled ‘A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF-α and Anti-OX40L NANOBODY® Molecule, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes.’ The study aims to evaluate the safety and efficacy of SAR442970 in preserving pancreatic β-cell function in individuals with newly diagnosed Type 1 Diabetes (T1D).
The intervention under investigation is SAR442970, a dual-action nanobody molecule targeting TNF-α and OX40L, administered via subcutaneous injection. The treatment’s purpose is to maintain pancreatic β-cell function in patients with T1D.
This interventional study employs a randomized, parallel assignment model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. Its primary purpose is treatment, with participants divided into SAR442970 and placebo groups in a 3:1 ratio.
The study began on February 28, 2025, with a primary completion date set for 52 weeks post-initiation. The estimated completion is anticipated after an additional 26-week safety follow-up, with the last update provided on July 15, 2025.
Sanofi’s study could significantly impact its stock performance by showcasing its commitment to innovative diabetes treatments. Positive results may enhance investor confidence, especially in a competitive market where advancements in diabetes care are highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.